eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2017
vol. 42
 
Share:
Share:
abstract:
Experimental immunology

Immune complex negatively regulates toll-like receptor 3-triggered tumour necrosis factor α production in B cells

Li Qian
,
Wenyan Chen
,
Shaoqing Wang
,
Yang Liu
,
Xiaoqin Jia
,
Yi Fu
,
Weijuan Gong
,
Fang Tian

(Centr Eur Immunol 2017; 42 (3): 223-230)
Online publish date: 2017/10/30
View full text Get citation
 
PlumX metrics:
Inappropriate activation of toll-like receptor 3 (TLR3) has been implicated in the pathogenesis of autoimmune diseases, so the negative regulation of TLR3-triggered immune response has received increasing attention. Nonpathogenic immune complex (IC) has been used as treatment for many inflammatory and autoimmune diseases. However, the role of IC in the regulation of TLR3-triggered immune responses and the underlying mechanisms need to be investigated. In this study we demonstrate that IC or intravenous immunoglobulin (Ig) stimulation of B cells attenuates polyinosinic:polycytidylic acid (poly I:C)-induced CD40 expression; IC, but not Ig, can significantly inhibit poly I:C-induced pro-inflammatory tumour necrosis factor α (TNF-α) production by B cells. Moreover, IC/Ig stimulation does not alter the expression of TLR3 in B cells. Further experiments suggest that receptor for the Fc portion of IgGIIb (FcγRIIb) is involved in the suppressive effect of IC on TLR3-mediated TNF-α production, but not CD40 expression. Thus, we provide a new means of negative regulation of TLR3-triggered immune responses in B cells via FcγRIIb, and we provide a new mechanistic explanation of the therapeutic effect of nonpathogenic IC on inflammatory or autoimmune diseases.
keywords:

B cells, FcγRIIb, immune complex, Toll-like receptor


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.